Xiaoer Annai Jinguan Changye (小儿安乃近灌肠液)小儿安乃近灌肠液
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 大庆华宇北药科技开发有限公司Chinese legal name: 大庆华宇北药科技开发有限公司
主要成分Active Ingredients
- 安乃近Annai Jin
药物知识说明
安乃近是一种在国家药监局注册认定的药品。该药品含有安乃近-6871c0e7等成分。
该药品关联的活性成分包括：安乃近Annai Jin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：大庆华宇北药科技开发有限公司Chinese legal name: 大庆华宇北药科技开发有限公司。
您可以探索含有相同成分的其他药品：安乃近-6871c0e7成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 小儿安乃近灌肠液) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 安乃近Annai Jin.
Manufacturers recorded for this product: 大庆华宇北药科技开发有限公司Chinese legal name: 大庆华宇北药科技开发有限公司.
Explore other medicines containing the same ingredient: 安乃近 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 小儿安乃近灌肠液Recorded Chinese name: 小儿安乃近灌肠液
- 规格Specification: 2ml:0.2g2 mL:0.2 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 大庆华宇北药科技开发有限公司Chinese legal name: 大庆华宇北药科技开发有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H23023696
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H23023696
Manufacturer
Chinese legal name: 大庆华宇北药科技开发有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H23023696
生产企业
大庆华宇北药科技开发有限公司(国产)
适应症
主要用于发热，也用于头痛、牙痛、肌肉痛、风湿性神经痛、急性关节炎的治疗等。
用法用量
直肠给药。使用前，需将塑料瓶口剪开。轻轻放入肛门内，将药液挤入即可。用量1次15～20mg/kg如需重复用药，一日不超,3次。
不良反应
1.本品可能引起过敏性皮疹或药物热，其中包括荨麻疹、渗出性红斑等。严重者可发生剥落性皮炎、大疱表皮松解症。
2.较长时间使用可引起粒细胞缺乏症，发生率约为1.1%，急性起病，重者有致命危险;亦可引起免疫性溶血性贫血、血小板减少性紫癜及再生障碍性贫血等。
禁忌
对吡唑酮类药有过敏史者禁用。
注意事项
1.非发热患者不可应用。
2.本品不应长期使用，使用超过一周以上，应检查白细胞数。
3.本品1次用量按体重不得超过20mg/kg。
4.本品与阿司匹林有交叉过敏反应。
贮藏
遮光，密封保存。
规格
2ml:0.2g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.